Double-blind Randomized Study to Evaluate the Immunogenicity and Reactogenicity of Two Different Lots of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Containing 1440 EL.U of Antigen Per mL and Injected According to a 0, 12 Month Schedule in Healthy Adult Volunteers
Phase of Trial: Phase IV
Latest Information Update: 24 Oct 2016
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary)
- Indications Hepatitis A
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 16 Jul 2015 Results of pooled analysis (n=122) of this and other trial (see profile 37121) were published in the Vaccine.
- 29 Apr 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 13 Sep 2008 New trial record.